首页 > 市场调查报告书 > 医疗设备

体外诊断液体活检

市场调查报告书

商品编码

1701010

液态切片市场规模、份额、成长分析、按产品、按循环生物标记、按技术、按应用、按临床应用、按样本类型、按最终用户、按地区 - 2025 年至 2032 年行业预测

Liquid Biopsy Market Size, Share, and Growth Analysis, By Product, By Circulating Biomarker, By Technology, By Application, By Clinical Application, By Sample Type, By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年04月03日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计2023年全球液态切片市场规模将达到76亿美元，2032年将达到269.5亿美元，预计在预测期内（2025-2032年）的复合年增长率为15.1%。

受癌症发病率上升、诊断技术的进步以及向微创检测方法转变的推动，液态切片市场预计将经历显着增长。正在进行的研究，特别是针对多种癌症早期检测 (MCED) 测试的研究，正在为市场扩张开闢新的途径。液态切片以其检测肿瘤基因变异的能力而闻名，它可以促进标靶治疗，FDA核准Guardant360 CDx 用于治疗 ESR1 突变乳癌证明了这一点。此外，政府越来越多地推出公共筛检倡议，进一步推动了使用血液和羊水等生物液体进行非侵入性检测的接受度。随着医疗保健需求的增加，特别是产前检测需求的增加，这个市场在未来几年可能会成长。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业市场定位（2024年）
主要市场参与者所采取的策略
近期市场趋势
公司市场占有率分析（2024年）
主要企业简介
- 公司详情
- 产品系列分析
- 公司分部份额分析
- 收益与前一年同期比较对比（2022-2024 年）
  主要企业简介
  - F. Hoffmann-La Roche Ltd（瑞士）
  - 赛默飞世尔科技公司（美国）
  - Illumina公司（美国）
  - Guardant Health, Inc.（美国）
  - Biocept公司（美国）
  - Sysmex株式会社（日本）
  - Natera公司（美国）
  - Biocartis Group NV（比利时）
  - Bio-Rad Laboratories, Inc.（美国）
  - OncoCyte公司（美国）
  - Adaptive BIoTechnologies Corporation（美国）
  - Angle PLC（英国）
  - Epic Science, Inc.（美国）
  - Neogenomics实验室（美国）
  - CellMax Life（美国）
  - 美纳里尼-硅生物系统公司（义大利）
  - Lunglife AI Inc.（美国）

结论和建议

简介目录

Product Code: SQMIG35J2060

Global Liquid Biopsy Market size was valued at USD 7.6 billion in 2023 and is poised to grow from USD 8.75 billion in 2024 to USD 26.95 billion by 2032, growing at a CAGR of 15.1% during the forecast period (2025-2032).

The liquid biopsy market is poised for significant growth, driven by the rising prevalence of cancer, advancements in diagnostic technology, and a shift towards minimally invasive testing methods. Continued research into liquid biopsy assays, particularly multi-cancer early detection (MCED) tests, is opening new avenues for market expansion. Liquid biopsies, known for their ability to detect genetic alterations in tumors, facilitate targeted therapies, as evidenced by the FDA's approval of Guardant360 CDx for ESR1 mutant breast cancer. Additionally, increasing government initiatives promoting public screening further boost acceptance of non-invasive tests using biological fluids like blood and amniotic fluid. As healthcare demands rise, especially in the context of prenatal testing, the market is well-positioned for growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liquid Biopsy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liquid Biopsy Market Segments Analysis

Global Liquid Biopsy Market is segmented by Product, Circulating Biomarker, Technology, Application, Clinical Application, Sample Type, End User and region. Based on Product, the market is segmented into Assay Kits, Instruments and Services. Based on Circulating Biomarker, the market is segmented into Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA, Extracellular Vesicles and Other Circulating Biomarkers. Based on Technology, the market is segmented into Multi-Gene Parallel Analysis Using NGS and Single-Gene Analysis Using PCR. Based on Application, the market is segmented into Cancer Applications and Non-Cancer Applications. Based on Clinical Application, the market is segmented into Therapy Selection, Treatment Monitoring, Early Cancer Screening and Recurrence Monitoring. Based on Sample Type, the market is segmented into Blood Samples and Other Sample Types. Based on End User, the market is segmented into Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liquid Biopsy Market

The global liquid biopsy market is significantly driven by the rising incidence of cancer worldwide. As more patients are diagnosed with various types, including lung, breast, colorectal, and prostate cancers, there is a growing demand for non-invasive diagnostic methods that facilitate early detection. Liquid biopsies offer a less painful alternative to traditional tissue biopsies, enabling real-time monitoring of tumor progression and assessing treatment responses. This innovative approach not only enhances patient outcomes but also improves survival rates, highlighting the importance of liquid biopsies in contemporary cancer care and fueling the expansion of this market segment.

Restraints in the Global Liquid Biopsy Market

The Global Liquid Biopsy market faces several significant restraints that hinder its widespread adoption. Despite the advantages it offers, the high costs associated with liquid biopsy diagnostic techniques pose a barrier, particularly in underdeveloped regions where healthcare budgets are limited. Additionally, many patients are unable to access treatments derived from liquid biopsy due to insufficient coverage by insurance plans and government health programs. Consequently, without clear reimbursement policies, healthcare providers may refrain from prescribing these tests, which further restricts market utilization and adoption rates. As a result, the growth potential of the liquid biopsy market remains constrained.

Market Trends of the Global Liquid Biopsy Market

The Global Liquid Biopsy market is increasingly leveraging Big Data Analytics and AI to enhance cancer diagnostics, driving significant innovation and growth within the sector. The integration of machine learning algorithms facilitates more precise classifications of tumors by analyzing distinct genetic alterations, enabling oncologists to make informed treatment decisions swiftly. This technological evolution is not only streamlining the diagnostic process but also leading to the discovery of novel biomarkers that enhance liquid biopsy accuracy. As the demand for minimally invasive testing continues to rise, the fusion of AI with traditional methodologies positions the liquid biopsy market for substantial expansion in the coming years.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Supply Chain Analysis
Patent Analysis
Regulatory Analysis
Technology Analysis
Case Studies

Global Liquid Biopsy Market Size by Product & Service & CAGR (2025-2032)

Market Overview
Assay Kits
Instruments
Services

Global Liquid Biopsy Market Size by Circulating Biomarker & CAGR (2025-2032)

Market Overview
Circulating Tumor Cells
Circulating Tumor DNA
Cell-Free DNA
Extracellular Vesicles
Other Circulating Biomarkers

Global Liquid Biopsy Market Size by Technology & CAGR (2025-2032)

Market Overview
Multi-Gene Parallel Analysis Using NGS
Single-Gene Analysis Using PCR

Global Liquid Biopsy Market Size by Application & CAGR (2025-2032)

Market Overview
Cancer Applications
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Other Cancers
Non-Cancer Applications
- Non-Invasive Prenatal Testing
- Organ Transplantation
- Infectious Disease Testing

Global Liquid Biopsy Market Size by Clinical Application & CAGR (2025-2032)

Market Overview
Therapy Selection
Treatment Monitoring
Early Cancer Screening
Recurrence Monitoring

Global Liquid Biopsy Market Size by Sample Type & CAGR (2025-2032)

Market Overview
Blood Samples
Other Sample Types

Global Liquid Biopsy Market Size by End User & CAGR (2025-2032)

Market Overview
Reference Laboratories
Hospitals & Physician Laboratories
Academic & Research Centers
Other End Users

Global Liquid Biopsy Market Size & CAGR (2025-2032)

North America (Product & Service, Circulating Biomarker, Technology, Application, Clinical Application, Sample Type, End User)
- US
- Canada
Europe (Product & Service, Circulating Biomarker, Technology, Application, Clinical Application, Sample Type, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product & Service, Circulating Biomarker, Technology, Application, Clinical Application, Sample Type, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product & Service, Circulating Biomarker, Technology, Application, Clinical Application, Sample Type, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product & Service, Circulating Biomarker, Technology, Application, Clinical Application, Sample Type, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocept, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocartis Group NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OncoCyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adaptive Biotechnologies Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Angle PLC (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Epic Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neogenomics Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CellMax Life (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Menarini-Silicon Biosystems (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lunglife AI Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments